本化疗方案的剂量限制毒性为骨髓抑制，其中72 %的病人发生3～ 4度中性粒细胞下降。
The dose limiting toxicity ssociated with this regimen was myelo suppression with grade 3~4 neutrocytopenia in 72 % of patients.
其剂量限制毒性(DLT)为中性粒细胞减少和腹泻，肝肾功能下降会降低最大耐受剂量(MTD)。
The dose limiting toxicity (DLT) of it was neutropenia and diarrhea. Its maximum tolerance dose (MTD) may be reduced by elevated liver or kidney function.
应用推荐